Evidence map›Paper›PMID 36450475›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.

Taro Edahiro, Hiroshi Ureshino, Ren Chishaki, Keita Fujino, Tatsuji Mino, Tetsumi Yoshida, Noriyasu Fukushima, Tatsuo Ichinohe

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Taro EdahiroDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Hiroshi UreshinoDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Ren ChishakiDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Keita FujinoDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tatsuji MinoDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Tetsumi YoshidaDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Noriyasu FukushimaDepartment of Internal Medicine, Karatsu Red Cross Hospital, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Hiroshima University · JPTakamatsu Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with acute myeloid leukemia (AML) harboring FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication mutation are associated with a poor survival outcome, even those receiving allogeneic stem cell transplantation (Allo-SCT). An additional treatment strategy with allo-SCT is therefore required to reduce relapse in these patients. Gilteritinib is a specific FLT3 inhibitor that has shown clinical benefit for patients with relapsed and refractory (R/R) AML harboring FLT3 mutation. We herein report a 49-year-old woman with R/R AML who was successfully treated with pre- and post-transplant gilteritinib. Post-transplant gilteritnib yielded a durable response with possible exacerbation of graft-versus-host disease.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePeripheral Blood Stem Cell TransplantationAniline CompoundsFemalefms-Like Tyrosine Kinase 3HumansMiddle AgedMutationPyrazinesAniline Compoundsfms-Like Tyrosine Kinase 3gilteritinibPyrazinesacute myeloid leukemiaallogenic stem cell transplantationFLT3 mutationgilteritinibgraft-versus-host diseasegraft-versus-leukemia effect

Identifiers

PMID36450475
PMCPMC10465286
OpenAlexW4310571233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.